View Older Stories View More Recent Stories
-
Mizuho Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
-
Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
-
BMO Capital Upgrades Sarepta Therapeutics (SRPT) to Outperform
-
BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)
-
Elanco to join S&P MidCap 400 as Sarepta moves to SmallCap 600
-
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
-
Mizuho on Sarepta Therapeutics (SRPT): 'Lowering 3Q25 Elevidys Sales Below Consensus'
-
Sarepta Therapeutics (SRPT) PT Lowered to $16 at BofA Securities, 'Debt refinancing mitigates liquidity risk but Elevidys launch remains overhang'
-
Citi Opens 90-Day Downside Catalyst Call on Sarepta Therapeutics (SRPT)
-
Sarepta sells $174 million in Arrowhead stock, triggers $100 million milestone
-
Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending - Hagens Berman
-
Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
-
TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)
-
Freedom Broker Upgrades Sarepta Therapeutics (SRPT) to Buy
-
Sarepta Therapeutics (SRPT) PT Raised to $14 at Citi
-
BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT) Following Mgmt. Meeting
-
Sarepta Therapeutics (SRPT) PT Raised to $50 at Wells Fargo
-
Sarepta Therapeutics (SRPT) Tops Q2 EPS by $1.32
-
Sarepta Therapeutics (SRPT) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending - Hagens Berman
-
RBC Capital weighs in on Sarepta Therapeutics (SRPT) related to two new FAERS Elevidys deaths
-
Sarepta Therapeutics (SRPT) PT Raised to $18 at Bernstein
-
Sarepta Therapeutics (SRPT) PT Raised to $19 at Mizuho
-
Sarepta Therapeutics (SRPT) PT Raised to $17 at TD Cowen
-
Barclays Upgrades Sarepta Therapeutics (SRPT) to Equalweight
-
Oppenheimer Upgrades Sarepta Therapeutics (SRPT) to Outperform
-
Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) PT Raised to $15 at Piper Sandler
-
Sarepta Therapeutics (SRPT) PT Raised to $50 at BMO Capital
-
Sarepta Therapeutics (SRPT) PT Raised to $5 at H.C. Wainwright
-
Sarepta Therapeutics (SRPT) call put ratio 1.7 calls to 1 put into FDA headlines
-
Bernstein SocGen Group Starts Sarepta Therapeutics (SRPT) at Market Perform
-
JPMorgan Upgrades Sarepta Therapeutics (SRPT) to Neutral
-
Sarepta Therapeutics (SRPT) to resume trading at 5:40 PM ET
-
FDA allows Sarepta to resume ELEVIDYS shipments for ambulatory patients
-
FDA lifts voluntary hold on Sarepta gene therapy for walking DMD patients
-
Sarepta Therapeutics (SRPT) Halted, News Pending
-
Arrowhead receives $100 million milestone from Sarepta for ARO-DM1 study
-
H.C. Wainwright Reiterates Sell, $0 PT on Sarepta (SRPT), 'see low likelihood of positive catalysts near-term'
-
Barclays Downgrades Sarepta Therapeutics (SRPT) to Underweight
-
Sarepta Therapeutics (SRPT) Tanks 36% After 3d Patient Death, SRPT Securities Class Action Pending; Investors With Substantial Losses And Persons With Knowledge Encouraged To Contact Hagens Berman
-
Sarepta receives negative EU opinion for Duchenne gene therapy ELEVIDYS
-
H.C. Wainwright Reiterates Sarepta (SRPT) at Sell, $0 price target, 'major blow to Sarepta'
-
Sarepta's Elevidys Fails to Get EU Approval - Bloomberg
-
Sarepta Therapeutics (SRPT) call put ratio 1 call to 1 put on 94K contracts
-
JPMorgan Downgrades Sarepta Therapeutics (SRPT) to Underweight
-
Sarepta Therapeutics (SRPT) Off Lows on Positive Chatter
-
Citi Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) PT Lowered to $35 at Jefferies
-
Sarepta (SRPT) would have to conduct new studies to get back on market, FDA official says - Endpoints
-
Citi Opens 90d Downside Catalyst Watch on Sarepta Therapeutics (SRPT)
